title: Design and development of novel azo prodrugs using various permutations and combinations of 5- and 4-aminosalicylic acids for inflammatory bowel disease: a colon-targeted approach.
abstract: Novel carrier-linked azo prodrugs of 4 and 5-aminosalicylic acids (4-ASA and 5-ASA respectively) using the same drugs as carriers in different permutations and combinations were designed for targeting colon affected with inflammatory bowel disease (IBD). Improved hydrophilic nature of the prodrugs assisted in minimizing their absorption in upper GIT and efficient delivery of the active drugs to colon as evidenced from their stability in aqueous buffers (pH 1.2 and 7.4) and upper GIT homogenates with 68-91% release on incubation with rat cecal matter. Amongst the series, 4A4AAZ (prodrug of 4-ASA with 4-ASA) at a dose of 53 mg/Kg was found to be the most promising candidate as it substantially alleviated the quantifying markers of colonic inflammation in TNBS-induced experimental colitis in Wistar rats. Moreover it displayed significantly lower GI toxicity (at ten times higher dose). 5-ASA- induced pancreatitis and sulfapyridine-induced adverse effects on liver that are characteristic of sulfasalazine were not observed with 4A4AAZ. It could be explored further as a potential candidate for IBD patients intolerant to pancreatitis induced by oral administration of 5-ASA.
authors.affiliation: Department of Pharmaceutical Chemistry, Bharati Vidyapeeth Deemed University, Poona College of Pharmacy, Pune-411038, Maharashtra, India. suneeladhaneshwar@rediffmail.com.
authors.forename: Dhaneshwar
authors.initials: D
authors.lastname: Suneela
authors.forename: Vadnerkar
authors.initials: V
authors.lastname: Gaurav
authors.forename: Rai
authors.initials: R
authors.lastname: Himanshu
mesh_terms: D010131:Aminosalicylic Acid / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D000818:Animals; D001391:Azo Compounds / Q000737:chemistry; D003092:Colitis / Q000139:chemically induced / Q000188:drug therapy*; D003106:Colon / Q000187:drug effects* / Q000473:pathology; D015195:Drug Design; D005260:Female; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D008297:Male; D019804:Mesalamine / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D023421:Models, Animal; D011355:Prodrugs / Q000737:chemistry; D051381:Rats; D017208:Rats, Wistar; D012460:Sulfasalazine / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry; D014302:Trinitrobenzenesulfonic Acid / Q000008:administration & dosage
chemical_list: D001391:Azo Compounds; D011355:Prodrugs; D012460:Sulfasalazine; D019804:Mesalamine; D010131:Aminosalicylic Acid; D014302:Trinitrobenzenesulfonic Acid